S&N sells wound care products
This article was originally published in The Gray Sheet
Advanced BioHealing acquires Smith & Nephew's Dermagraft tissue-engineered dermal replacement product for full-thickness diabetic foot ulcers and TransCyte temporary wound cover for serious burns. The May 31 product purchase, for undisclosed terms, dovetails with the start-up firm's R&D efforts in tissue engineering; the firm has a pending IDE for a keratinocyte-based bioengineered wound covering that does not require deep frozen storage. S&N indicated its interest in divesting the products in October 2005 to boost its "growth profile" after receiving an FDA "non-approvable" letter for an expanded Dermagraft indication to treat venous leg ulcers...
You may also be interested in...
Device VC activity increases
Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.
A review by a government watchdog found the FDA’s review process for COVID-19 diagnostics was plagued by issues including allowing low-quality tests to slip through, high reviewer workloads, and manufacturer frustration.